CoChat

Cost‐effectiveness of grass allergen tablet (GRAZAX®) for the prevention of seasonal grass pollen induced rhinoconjunctivitis – a Northern European perspective

Bachert, C., Vestenbæk, U., Christensen, J., Griffiths, U. K., Poulsen, P. B. · 2007 · Clinical & Experimental Allergy
Cited by 95

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

Summary: Background The prevalence of allergic rhinoconjunctivitis has increased dramatically. Seventeen million people in the United Kingdom, Germany, the Netherlands, Sweden, Denmark, Norway and Finland suffer from grass pollen induced allergic rhinitis. Symptomatic therapy with antihistamines and topical steroids is partially effective but allergen‐specific immunotherapy by injection or sublingual routes is superior. The grass allergen tablet (GRAZAX®) is a new allergen‐specific immunotherapy for home administration. Objective To assess the cost‐effectiveness of the grass allergen tablet compared with symptomatic medication in seven Northern European countries. Methods A prospective pharmacoeconomic analysis was carried out alongside a multinational clinical trial. Pooled data on resource use and health outcomes were collected. A societal perspective was adopted, and the analysis had a 9‐year time horizon. The outcome measure was Quality Adjusted Life Years (QALYs). Results The grass allergen tablet was clinically superior to symptomatic treatment, producing statistically significant differences for all efficacy end‐points, including the number of QALYs gained – 0.976 vs. 0.947 QALYs gained. There was a significantly higher usage of the rescue medications loratadine and budesonide, and more hours missed from work (production loss), in the symptomatic treatment group. The cost per QALY gained in the grass allergen tablet group was similar in the seven countries (€12 930 to €18 263 for an annual cost of the grass allergen tablet of €1500). The analysis showed that the grass allergen tablet was cost‐effective for all countries for an annual treatment cost below €2200. Conclusion The pharmacoeconomic analysis illustrated that allergen‐specific immunotherapy with the grass allergen tablet is a cost‐effective intervention for the prevention of grass pollen induced rhinoconjunctivitis in Northern European countries, for a tablet price below €6. In Germany for example the price of the tablet is €2.95 corresponding to a yearly treatment cost of €358 – based on a 9‐year time horizon.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1365-2222.2007.02706.x

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 95

Metadata

Authors
Bachert, C., Vestenbæk, U., Christensen, J., Griffiths, U. K., & Poulsen, P. B.
Venue
Clinical & Experimental Allergy
Publisher
Wiley
Published
2007-04-20
Volume
37
Issue
5
Pages
772-779
ISSN
  • 0954-7894 (ISSN-L)
  • 1365-2222
OpenAlex
W2034746950
Cited by
95
References
7
FWCI
5.77
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cost‐effectiveness of grass allergen tablet (GRAZAX®) for the prevention of seasonal grass pollen induced rhinoconjunctivitis – a Northern European perspective. https://app.cochat.ai/papers/10.1111/j.1365-2222.2007.02706.x
The paper
Bachert, C., Vestenbæk, U., Christensen, J., Griffiths, U. K., & Poulsen, P. B. (2007). Cost‐effectiveness of grass allergen tablet (GRAZAX®) for the prevention of seasonal grass pollen induced rhinoconjunctivitis – a Northern European perspective. Clinical & Experimental Allergy. https://doi.org/10.1111/j.1365-2222.2007.02706.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.